Printer Friendly

CURRENT TECHNOLOGY CORPORATION REPORTS IT INTENDS TO SUBMIT TO THE FDA

 VANCOUVER, British Columbia, Feb. 23 /PRNewswire/ -- Current Technology Corporation (the "Company") (NASDAQ: CRTC) reports its decision to submit a Pre-Market Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its pulsed electrical stimulation medical device for the intended use of reducing hair shedding in males with androgenetic alopecia (common baldness).
 Clinical data received from the Company's independent statisticians on the multi-center clinical trial involving male subjects indicates that, based on global assessment data, there is statistically significant diminished hair shedding in those male subjects completing active treatments when compared to male subjects receiving simulated treatments. Safety of the device also appears to be confirmed by the data received. Insufficient statistical data has been obtained at this time to support a claim of hair regrowth.
 Preparation of the PMA is under way. It will be completed and submitted as quickly as possible. The Company cannot guarantee that the PMA will be accepted for filing, nor can it guarantee if, or when, FDA approval will be obtained. If the device receives FDA approval, the Company anticipates following its proposed marketing plan of placing its device with dermatologists and other interested physicians.
 In the meantime, the Company will direct attention to dealing with health regulatory agencies in other countries, with a view to seeking necessary approvals and marketing the device worldwide.
 -0- 2/23/93
 /CONTACT: Robert K. Kramer, CFO, Current Technology Corporation, 604-684-2727; or Tom Laughran or Gale Strenger, 708-564-5610, Mark Perlgut, 212-874-6800, or Earle Brown, 813-796-1452, all of The Investor Relations Company, for Current Technology Corporation/
 (CRTC)


CO: Current Technology Corporation ST: British Columbia IN: MTC SU: PDT

JG -- DE014 -- 9451 02/23/93 13:27 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 23, 1993
Words:280
Previous Article:FORD CHAIRMAN URGES ACTION ON ECONOMIC ILLS
Next Article:HOLIDAY RV SUPERSTORES, INC. REPORTS 1ST QUARTER REVENUES UP 39 PERCENT
Topics:


Related Articles
CURRENT TECHNOLOGY RETAINS THE WALL STREET GROUP FOR FINANCIAL PUBLIC RELATIONS AND INVESTOR RELATIONS SERVICES
OSTEOTECH POSITION ON GRAFTON(R) ACCEPTED BY FDA; GRAFTON(R) DEMINERALIZED BONE MATRIX DESIGNATED AS BANKED HUMAN TISSUE
SOMANETICS ANNOUNCES THIRD QUARTER RESULTS
FDA NOTIFIES INTEGRA LIFESCIENCES CORPORATION THAT PMA FOR ARTIFICIAL SKIN IS APPROVABLE
NEW AIDS SCREENING TEST DETECTS VIRUS EARLIER Coulter to Offer Blood and Plasma Collection Centers p24 Antigen Assay
MINNTECH ANNOUNCES DELAY IN INTRODUCTION OF NEW BIOCOR* OXYGENATOR
UROMED CORPORATION ANNOUNCES REGULATORY UPDATE
Integra LifeSciences Forms Clinical Research Department and Appoints Clinical Research Director
Mentor Receives Canadian Approval for Ultrasonic Liposuction

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters